Cantor Fitzgerald Comments on LMAT FY2025 Earnings

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for LeMaitre Vascular in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn expects that the medical instruments supplier will post earnings per share of $2.22 for the year. Cantor Fitzgerald currently has a "Neutral" rating and a $96.00 price objective on the stock. The consensus estimate for LeMaitre Vascular's current full-year earnings is $1.94 per share.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, beating analysts' consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The firm had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. During the same period last year, the firm earned $0.33 earnings per share. The business's quarterly revenue was up 15.6% compared to the same quarter last year.

A number of other research firms also recently issued reports on LMAT. Oppenheimer restated an "outperform" rating and set a $93.00 price objective (up previously from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. Barrington Research lifted their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an "outperform" rating in a research note on Friday, November 1st. Finally, StockNews.com downgraded shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a research note on Friday, December 13th. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, LeMaitre Vascular presently has an average rating of "Moderate Buy" and an average target price of $94.57.

LeMaitre Vascular Trading Down 0.9 %

Shares of LMAT traded down $0.88 during trading hours on Wednesday, reaching $98.77. 63,665 shares of the stock traded hands, compared to its average volume of 141,248. The stock has a fifty day simple moving average of $98.35 and a 200 day simple moving average of $92.07. LeMaitre Vascular has a 52 week low of $56.04 and a 52 week high of $109.58. The company has a market cap of $2.22 billion, a price-to-earnings ratio of 53.97, a PEG ratio of 2.19 and a beta of 0.96.

Hedge Funds Weigh In On LeMaitre Vascular

Several hedge funds have recently made changes to their positions in the business. Envestnet Asset Management Inc. increased its position in LeMaitre Vascular by 0.7% during the 2nd quarter. Envestnet Asset Management Inc. now owns 215,841 shares of the medical instruments supplier's stock valued at $17,759,000 after purchasing an additional 1,520 shares during the period. Canada Pension Plan Investment Board purchased a new position in shares of LeMaitre Vascular during the second quarter valued at about $82,000. Sei Investments Co. raised its stake in LeMaitre Vascular by 2.0% in the second quarter. Sei Investments Co. now owns 59,211 shares of the medical instruments supplier's stock worth $4,872,000 after buying an additional 1,140 shares in the last quarter. Public Sector Pension Investment Board raised its stake in LeMaitre Vascular by 8.3% in the second quarter. Public Sector Pension Investment Board now owns 43,999 shares of the medical instruments supplier's stock worth $3,620,000 after buying an additional 3,379 shares in the last quarter. Finally, Alpha DNA Investment Management LLC bought a new position in LeMaitre Vascular in the second quarter worth about $499,000. 84.64% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Bridget A. Ross sold 3,750 shares of the business's stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $101.47, for a total transaction of $380,512.50. Following the transaction, the director now owns 2,278 shares in the company, valued at $231,148.66. The trade was a 62.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 10.79% of the stock is owned by insiders.

LeMaitre Vascular Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, December 5th. Stockholders of record on Thursday, November 21st were issued a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.65%. The ex-dividend date of this dividend was Thursday, November 21st. LeMaitre Vascular's dividend payout ratio is 34.97%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.